Patents Assigned to Starton Therapeutics, Inc.
  • Treatment of vomiting and nausea with minimum dose of olanzapine
    Patent number: 11975112
    Abstract: Compositions, devices, and methods for transdermal administration of olanzapine and uses thereof, e.g., to treat nausea and vomiting.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: May 7, 2024
    Assignee: Starton Therapeutics, Inc.
    Inventors: James Oliver, Fotios Plakogiannis, Tamanna Lather, Marina Borovinskaya, Nisarg Modi, Rod L. Hartwig
  • Continuous delivery of lenalidomide and other immunomodulatory agents
    Patent number: 11197852
    Abstract: Provided are methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: December 14, 2021
    Assignee: Starton Therapeutics, Inc.
    Inventors: Marina Borovinskaya, Fotios Plakogiannis, Nisarg Modi, Tamanna Lather, Rod L. Hartwig, James C. Oliver, Yuliya Levintova